Cargando…

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review

Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well known for the treatment of erectile dysfunction. However, their use in the presence of pulmonary hypertension can cause ophthalmologic side effects, including non-arteritic optic ischemic neuropathy, chorioretinopa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barroso, Francisco, Ribeiro, João Crispim, Miranda, Eduardo P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PUBLISHED BY KNOWLEDGE E 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126729/ https://www.ncbi.nlm.nih.gov/pubmed/34055262 http://dx.doi.org/10.18502/jovr.v16i2.9088

Ejemplares similares

Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review
por: da Cruz, Natasha Ferreira Santos, et al.
Publicado: (2020)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia
por: Alshahrani, Saad, et al.
Publicado: (2016)

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss
por: Barreto, Monique Antunes de Souza Chelminski, et al.
Publicado: (2015)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Efficacy of phosphodiesterase type 5 inhibitors for the treatment of distal ureteral calculi: A systematic review and meta-analysis
por: Montes Cardona, Carlos Eduardo, et al.
Publicado: (2017)

Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder
por: Balog, Brian M., et al.
Publicado: (2019)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
por: Jackson, G, et al.
Publicado: (2010)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
por: Corinaldesi, C., et al.
Publicado: (2015)

Revisiting the halogen bonding between phosphodiesterase type 5 and its inhibitors
por: Jedwabny, Wiktoria, et al.
Publicado: (2019)

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
por: Mondaini, Nicola
Publicado: (2020)

The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review
por: Peixoto, Christina Alves, et al.
Publicado: (2015)

Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study
por: Song, Seung-Hun, et al.
Publicado: (2021)

Musculoskeletal effects of obesity and bariatric surgery – a narrative review
por: Holanda, Narriane, et al.
Publicado: (2022)

Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review
por: Wang, Jie, et al.
Publicado: (2017)

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver
por: Halverscheid, Leonie, et al.
Publicado: (2009)

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
por: Newby, Danielle
Publicado: (2022)

Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
por: Corbic, Milena, et al.
Publicado: (2023)

The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review
por: Pauls, Mathilde MH, et al.
Publicado: (2017)

Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis
por: Feng, Shijian, et al.
Publicado: (2018)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
por: Moschos, Marilita M, et al.
Publicado: (2016)

Effect of Phosphodiesterase Inhibitor on Diabetic Nephropathy
por: Kang, Shin-Wook
Publicado: (2012)

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History
por: Elhwuegi, AS
Publicado: (2016)

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
por: Zucchi, A., et al.
Publicado: (2019)

Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate
por: Zhang, Wenhao, et al.
Publicado: (2015)

Phosphodiesterase type 5 and cancers: progress and challenges
por: Barone, Ines, et al.
Publicado: (2017)

Effect of DA-8159, a Selective Phosphodiesterase Type 5 Inhibitor, on Electroretinogram and Retinal Histology in Rabbits
por: Cho, Ho Kyun, et al.
Publicado: (2004)

Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples
por: Song, Seung-Hun, et al.
Publicado: (2016)

Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis
por: Machen, G. Luke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v9mldc98rbfm2kicc6fagj0tq3